Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed (LENDEXAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01194791
Recruitment Status : Completed
First Posted : September 3, 2010
Last Update Posted : April 25, 2017
Information provided by (Responsible Party):
PETHEMA Foundation